-
1.发明申请PHOSPHODIESTERASE 4D7 AS MARKER FOR MALIGNANT, HORMONE-SENSITIVE PROSTATE CANCER 有权PHOSPHODIESTERASE 4D7作为恶性肿瘤标志物，敏感性前列腺癌公开(公告)号：US20120129788A1
公开(公告)日：2012-05-24
申请号：US13320050
申请日：2010-05-11
IPC分类号： A61K38/17 , G01N33/574 , C12Q1/68 , A61P35/00 , C07K16/40 , C12Q1/44 , G01N33/573 , C07H21/02 , C12N9/16 , C07H21/00
CPC分类号： C12Q1/6886 , C12N9/16 , C12N15/1137 , C12N15/115 , C12N2310/11 , C12N2310/14 , C12N2310/16 , C12Q1/44 , C12Q2600/106 , C12Q2600/112 , C12Q2600/158 , C12Y301/04017 , G01N33/57434 , G01N2800/52
摘要： The present invention relates to phosphodiesterase 4D7 (PDE4D7) for use as a marker for malignant, hormone-sensitive prostate cancer, wherein the expression of the marker is increased when comparing the expression in malignant, hormone-sensitive prostate cancer tissue, to the expression in normal tissue or benign prostate tumor tissue, and the use of PDE4D7 as a diagnostic marker for malignant, hormone-sensitive prostate cancer. The present invention also relates to a composition for diagnosing, detecting, monitoring or prognosticating malignant, hormone-sensitive prostate cancer, a corresponding detection method, a method allowing to discriminate between a benign and malignant hormone-sensitive prostate cancer and a method of data acquisition, as well as corresponding immunoassays. The present invention also relates to a method of identifying an individual for eligibility for malignant, hormone-sensitive prostate cancer as well as an immunoassay for stratifying an individual with such prostate cancer. The present invention further envisages pharmaceutical compositions and their use for the treatment of malignant, hormone-sensitive prostate cancer.
摘要翻译： 本发明涉及用作恶性，激素敏感性前列腺癌的标记物的磷酸二酯酶4D7（PDE4D7），其中当将恶性，激素敏感性前列腺癌组织中的表达与恶性，激素敏感性前列腺癌组织中的表达比较时，标志物的表达增加 正常组织或良性前列腺肿瘤组织，并使用PDE4D7作为恶性，激素敏感性前列腺癌的诊断标记。 本发明还涉及用于诊断，检测，监测或预测恶性，激素敏感性前列腺癌的组合物，相应的检测方法，允许区分良性和恶性激素敏感性前列腺癌的方法和数据采集方法 ，以及相应的免疫测定。 本发明还涉及鉴定个体对恶性，激素敏感性前列腺癌的资格的方法以及用这种前列腺癌分层个体的免疫测定法。 本发明进一步设想药物组合物及其用于治疗恶性，激素敏感性前列腺癌的用途。
搜索结果
1 条记录 (耗时 0.009 秒)
